1型糖尿病
医学
胰岛素
自身抗体
免疫疗法
小岛
疾病
免疫学
糖尿病
自身免疫性疾病
临床试验
胰岛
胰腺
生物信息学
内科学
内分泌学
免疫系统
生物
抗体
作者
Colin Dayan,Rachel Besser,Richard A. Oram,William Hagopian,Manu Vatish,Owen Bendor-Samuel,Matthew D. Snape,John A. Todd
出处
期刊:Science
[American Association for the Advancement of Science (AAAS)]
日期:2021-07-29
卷期号:373 (6554): 506-510
被引量:71
标识
DOI:10.1126/science.abi4742
摘要
Type 1 diabetes (T1D) is an autoimmune disease in which the insulin-producing β cells of the pancreas are destroyed by T lymphocytes. Recent studies have demonstrated that monitoring for pancreatic islet autoantibodies, combined with genetic risk assessment, can identify most children who will develop T1D when they still have sufficient β cell function to control glucose concentrations without the need for insulin. In addition, there has been recent success in secondary prevention using immunotherapy to delay the progression of preclinical disease, and primary prevention approaches to inhibiting the initiating autoimmune process have entered large-scale clinical trials. By changing the focus of T1D management from late diagnosis and insulin replacement to early diagnosis and β cell preservation, we can anticipate a future without the need for daily insulin injections for children with T1D.
科研通智能强力驱动
Strongly Powered by AbleSci AI